Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 19/20 | 0.69 |
| ▸ | BRAF | P15056 | 17/20 | 0.69 |
| ▸ | KDR | P35968 | 2/20 | 0.64 |
| ▸ | LCK | P06239 | 1/20 | 0.60 |
| ▸ | FYN | P06241 | 1/20 | 0.60 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.60 |
| ▸ | KIT | P10721 | 1/20 | 0.60 |
| ▸ | FLT1 | P17948 | 1/20 | 0.60 |
| ▸ | FLT4 | P35916 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13504182 | 0.92 | RAF1 (0.68) | RAF1BRAFKDRLCKFYN | |
| SCHEMBL2889750 | 0.92 | RAF1 (0.70) | RAF1BRAFKDRLCKFYN | |
| SCHEMBL2886257 | 0.91 | RAF1 (0.75) | RAF1BRAFKDRLCKFYN | |
| SCHEMBL13504359 | 0.90 | RAF1 (0.72) | RAF1BRAFKDRLCKFYN | |
| SCHEMBL2892351 | 0.88 | RAF1 (0.71) | RAF1BRAFKDRLCKFYN | |
| SCHEMBL13559553 | 0.88 | RAF1 (0.69) | RAF1BRAFKDRLCKFYN | |
| SCHEMBL2895074 | 0.88 | RAF1 (0.73) | RAF1BRAFKDRLCKFYN | |
| SCHEMBL2887114 | 0.87 | RAF1 (0.68) | RAF1BRAFKDRLCKFYN | |
| SCHEMBL13504239 | 0.87 | RAF1 (0.70) | RAF1BRAFKDRLCKFYN | |
| SCHEMBL13504296 | 0.87 | RAF1 (0.70) | RAF1BRAFKDRLCKFYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299108-B2 | for treatment of hematological/hormone-dependent cancer | NOVARTIS AG (CH) | 2012-10-30 | — | — | US | disclosed |
| US-8299108-B2 | for treatment of hematological/hormone-dependent cancer | NOVARTIS AG (CH) | 2012-10-30 | — | — | US | disclosed |